Lipoprotein(a) and the Early Diagnosis, Complexity, and Extent of Coronary Artery Disease and Myocardial Infarction

Area of Science:

• Cardiology
• Lipid Metabolism
• Cardiovascular Risk Factors

Background:

• Lipoprotein(a) [Lp(a)] is a recognized, independent causal risk factor for coronary artery disease (CAD).
• Understanding the clinical implications of elevated Lp(a) is crucial for cardiovascular risk stratification.

Purpose of the Study:

• To investigate the association between very high Lp(a) levels and the diagnosis, clinical presentation, and angiographic features of obstructive CAD.
• To evaluate the impact of Lp(a) on the occurrence of myocardial infarction (MI), including ST-segment elevation MI and recurrent MI.

Main Methods:

• A case-control study involving 446 individuals with very high Lp(a) (>230 nmol/L) and 223 controls with low Lp(a) (≤7 nmol/L).
• Propensity score matching was used to balance groups by age and sex.
• Kaplan-Meier analysis assessed CAD- and MI-free survival; multivariable logistic regression analyzed associations with multivessel disease and SYNergy Between percutaneous coronary intervention with TAXus and Cardiac Surgery-1 (SYNTAX) score.

Main Results:

• Individuals with very high Lp(a) exhibited significantly lower event-free survival for obstructive CAD diagnosis and MI occurrence (P=0.006 and P=0.012, respectively).
• Elevated Lp(a) was associated with multivessel CAD (adjusted OR: 1.43 per 100 nmol/L; P=0.028).
• Very high Lp(a) carriers had a 2.4-fold higher risk of ST-segment elevation MI and a 15.9-fold higher risk of recurrent MI compared to controls.

Conclusions:

• Very high Lp(a) levels are associated with an earlier onset of obstructive CAD and MI, particularly ST-segment elevation MI.
• Individuals with very high Lp(a) demonstrate a substantially elevated risk for recurrent MI, underscoring the need for targeted management strategies.